Articles from GenVivo, Inc.

PASADENA, Calif., April 26, 2025 (GLOBE NEWSWIRE) -- GenVivo, Inc., a clinical-stage biopharmaceutical company pioneering a patented, off-the-shelf vector platform that fights cancer by activating the patient’s immune system against the breadth of the patient’s own tumor antigens, is presenting compelling preclinical data on GEN-1013, an Interleukin-12 (IL-12) immunotherapy, at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25th – 30th, in Chicago, IL.

PASADENA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- GenVivo, Inc. (GVO) a private, clinical stage biopharmaceutical company with breakthrough “off-the-shelf” gene vector immunotherapies to treat cancer, announces the presentation of GEN2 Phase 1 clinical trial results in adult patients with hepatocellular carcinoma or tumors metastatic to the liver (NCT04313868), at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-10, in Houston, TX.

PASADENA, Calif., June 27, 2024 (GLOBE NEWSWIRE) --  GenVivo, Inc., a private, clinical-stage biopharmaceutical company with breakthrough off-the-shelf platforms for cancer gene medicine immunotherapies, announced that it has dosed the first US patient in a Phase I/Ib, open-label, dose-escalation and expansion clinical trial of GEN2. GEN2, GenVivo’s first product candidate to enter clinical development, is a non-replicating mRNA gene therapy vector being developed as a cancer immunotherapy to both kill tumors and activate a patient’s immune system against their individual cancer antigens (neoantigens). GEN2 is an off-the-shelf medicine, providing the advantages of a personalizing therapy without the time delays and expense associated with autologous products or tumor genome sequencing.